Key Takeaways
- API engine steady, new businesses drag reported profit: API revenue grew 6% YoY to ₹215 crores with 60%+ gross margins, but consolidated EBITDA of ₹45 crores was weighed down by ~₹23 crores of operating expenses from CDMO and injectables units that had no corresponding revenue in Q1.
- The biomanufacturing bet is now a contracted reality: A 5-year take-or-pay insulin deal, a 10-year US alternate protein deal, and an advanced-stage European term sheet underpin a planned 4x fermentation capacity expansion, with Phase 1 construction starting Q3 FY27.
- Complex injectables licensing is a whisker away from a definitive deal: A term sheet with a large US pharma multinational for the DCV platform is at an advanced stage, with a definitive agreement expected early Q3 FY27 and a second ANDA filing on track for Q4.
- Management is guiding 20% revenue growth for FY27, but the shape is back-end loaded: The target carries a ±5% band due to global uncertainty, and the ramp depends on milestone cash flows and first biotech CDMO revenues arriving only in Q4.
- What to watch next quarter: Signing of the definitive DCV licensing agreement, the European biotech CDMO contract, and any quantification of the H2 milestone payments that are expected to fully offset the full-year opex drag from new businesses.
The Biomanufacturing Opportunity: Contracted Demand Meets Capacity Build
- Demand signal is concrete, not speculative: Two signed take-or-pay agreements (5-year insulin drug substance, 10-year US alternate protein) and one advanced-stage European term sheet already consume most of the existing 400 kL Phase 0 capacity and drive the need for a 600 kL expansion in Phase 1.
- Capacity build is customer-funded and phased: Phase 1 is a 600 kL brownfield starting construction in Q3 FY27 with a 15–18 month build time, tied to a customer with a signed term sheet; Phase 2 will follow, and capex will be funded through a mix of internal accruals and partner capital where customers put skin in the game for dedicated facilities built on an exclusivity basis.
- The pipeline extends well beyond current signings: Over half a dozen potential customers are in advanced-stage discussions, each potentially requiring million-liter fermentation capacity, against a backdrop management frames as a once-in-a-generation industrial shift where global fermentation demand will soon be measured in over a billion liters while current capacity is still in the few millions.
- Take-or-pay contracts de-risk the investment: Multi-year, exclusivity-based agreements require customers to pay even if they do not utilize capacity, with no profit sharing and charges on a time-and-service basis, though management declined to disclose specific revenue-per-liter benchmarks citing confidentiality.
- The moat is cost and the ability to cross the scale-up "valley of death": Management claims one of the lowest capital costs per kiloliter of fermentation capacity globally, and positions the CDMO as bridging the gap between proving a molecule can be made and proving it can be made competitively and profitably at commercial scale.
Satwani: "I personally believe biomanufacturing is rapidly becoming one of the most consequential industrial shifts of our time..."
Complex Injectables: The DCV Platform Nears Commercial Inflection
- Licensing deal with a US pharma major is imminent: A term sheet was signed in August 2026 for DCV platform products, the definitive agreement is at an advanced stage and expected to be signed early Q3 FY27, described as "just a whisker away."
- The product pipeline is ahead of the capacity curve: Five to six DCV products are already developed and entering validation at the plant level very soon; the first ANDA was filed in September 2026, a second filing is on track for Q4 FY27, and approvals are expected in FY27–FY28.
- Capacity constraints may force a second line sooner than planned: Management is more worried about capacity than the number of products, citing partner estimates of demand traction that already exceed the current line's limited capacity, making a second line likely "very, very soon."
Satwani: "Trust me here, we are not worried about so-called the number of products. We are more worried about our capacities, because the kind of traction that we're seeing and kind of estimation that we are getting from our partner who are going to distribute our products in this advanced market, it looks like that we may have to come up with our second line very, very soon..."
New Business Financials: The Drag-and-Recovery Mechanics
- Q1 consolidated profit understates true earnings power: New businesses (biotech CDMO and complex injectables) contributed ~₹23 crores of operating expenses and ~₹11 crores of depreciation in Q1 FY27, costs that were previously capitalized as pre-operative expenses and did not flow through the P&L in the year-ago quarter, with no corresponding revenue in Q1.
- The recovery is back-end loaded and milestone-dependent: First biotech CDMO revenues are expected in Q4 FY27, and management states that H2 (Q3, Q4) milestone revenues described as "substantial multi-million dollars" will fully offset the full-year opex drag from both subsidiaries.
- FY26 provides a precedent for lumpy milestone recognition: The prior year included roughly ₹33 crores of milestone revenue from CDMO and injectables, all recognized in Q4; these are periodical, not consistent quarter-on-quarter.
- Management declined to quantify milestone specifics: Citing confidentiality agreements, no per-milestone amounts or frequency were disclosed, only the high-level assurance that they will set off the full-year opex.
- New business margin profile is guided only by industry reference: Management expects gross margins higher than 70% and EBITDA margins higher than 35%, in line with industry trends for differentiated fermentation biotech CMOs and dual-chamber device platforms, but declined to give forward-looking guidance.
Core API Business: The Steady Compounder
- Volume-led growth with margin resilience: Q1 FY27 API revenue grew 6% YoY to ₹215 crores and EBITDA grew 9% YoY to ₹66 crores, driven by sales volume growth and a strong gross margin mix, with gross margins remaining above 60%.
- Backward integration is the margin shield: Over a decade of investment in a fermentation biotech platform created "make versus buy" flexibility across most of the portfolio, insulating margins from supplier pricing moves and input cost volatility.
- Margin sustainability is high, with small caveats: Gross margins around 60% and EBITDA margins close to 30% are expected to continue; some point movements are possible from global uncertainties in logistics, shipping costs, and solvent prices where the company is not backward-integrated, but the trend is improving over time as the mix shifts toward higher-value regulated-market products.
- The competitive moat is customer stickiness built over decades: Management describes a displacement-resistant position where the time it took to get into customers is matched by the time it would take competitors to dislodge them, reinforced by product and geography mix shifts toward more valuable items.
- API will remain dominant near-term but shrink as a share of the whole: API is expected to be over 90% of FY27 revenue, but management sees it falling to definitely less than half of total sales in 5–6 years as new businesses scale.
Satwani: "It took me ages to get into these customers, but I can see that it will take them -- it will take ages for any other competition of ours to come and displace us."
Capex, Capacity, and the Funding Model
- Capex is demand-led, not speculative: Minimum ₹200–250 crores per year for the next 2–3 years from operating cash flows, with acceleration possible if more opportunities materialize; capex will be dictated by customer contracts.
- The "bait" strategy converts trial into committed expansion: Existing 400 kL Phase 0 capacity is used as a proving ground: customers come, use it, and in the interim the company builds dedicated Phase 1 facilities for them, with customers willing to wait 15–18 months given the economics and limited alternatives.
- Asset turnover is expected above 1x for biomanufacturing: Management gave this high-level benchmark but declined to provide specific numbers at this early stage.
- Biologics is a separate, later-stage opportunity: The plant is ready and about to enter validation, but revenue is not expected until early FY28 due to stability studies and DCGI approval timelines; no clinical trials are required since the unit will operate as a CMO for existing Indian biologics companies.
Satwani: "Trust me, these customers do not have many choices given the economics that we're offering them, given the capability and capacity. I think they are willing to wait for another 15 to 18 months once this new facility is up and running for them."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| FY27 revenue growth | 20% growth, ±5% band due to global uncertainties | FY27 full year |
| FY27 EBITDA growth | 25% growth, ±5% band due to global uncertainties | FY27 full year |
| DCV definitive licensing agreement | Term sheet signed, definitive agreement at advanced stage | Early Q3 FY27 |
| DCV second ANDA filing | Second product filing | Q4 FY27 |
| Biotech CDMO first revenue | Small revenues commence | Q4 FY27 |
| Biotech CDMO Phase 1 construction start | 600 kL brownfield, 15–18 month build | Q3 FY27 (construction starting Q3 itself as '27) |
| H2 milestone revenue | Fully offset full-year opex drag from both new subsidiaries | H2 FY27 (Q3, Q4) — management stated milestone revenues in Q3, Q4 will set off the opex drag |
| Biologics revenue commencement | Post-validation, stability, and DCGI approval | Early FY28 |
| API share of total sales (5–6 year view) | Definitely less than half of total sales (from >90% currently) | FY31–FY32 |
| Capex run-rate | Minimum ₹200–250 crores per year from operating cash flows | Next 2–3 years |
| Fermentation capacity expansion (Phase 1) | 4x current capacity | Next 2–3 years |
| R&D spend | Continue at 3–4% of sales, slight increase to about 5% in future | Ongoing |
Key Metrics
| Metric | Q1 FY27 |
|---|---|
| Consolidated revenue | ₹218 cr, +7% YoY |
| API revenue | ₹215 cr, +6% YoY, driven by volume increase |
| API gross margin | 60%+, currently much higher than 60%; base expectation around 60% |
| API EBITDA | ₹66 cr, +9% YoY |
| Consolidated EBITDA | ₹45 cr |
| Consolidated net profit | ~₹14 cr |
| New businesses opex drag | ~₹23 cr in Q1; expected to continue as run rate for next 2–3 quarters |
| New businesses depreciation drag | ~₹11 cr in Q1; expected to continue as run rate for next 2–3 quarters |
| Revenue growth target FY27 | 20%, consolidated, plus-minus ~5% due to global uncertainties |
| EBITDA growth target FY27 | 25%, consolidated, plus-minus ~5% due to global uncertainties |
| Net debt | ₹398 cr as of 30 June 2026; roughly ₹326 cr as of late September 2026 post-IPO proceeds |
| Capex incurred in Q1 | ~₹68 cr |
| API capacity utilization | 70%–80% |
| R&D spend | 3% to 5% of sales consistently; expected to continue with slight increase to ~5% |
| Fermentation capacity (Ujjain) | 400 kL large-scale fermentation; Phase 1 brownfield expansion of 600 kL starting Q3 FY27 |